Truist Financial Sticks to Their Buy Rating for Scholar Rock Holding (SRRK)
Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on Scholar Rock Holding (SRRK – Research Report) today. The company’s ...
Hosted on MSN8h
Eli Lilly Expands Zepbound Vial Dose Options, Cuts Weight-Loss Drug's Prices for Self-Pay Patients
Eli Lilly (LLY) on Tuesday launched higher doses of Zepbound, or tirzepatide, in single-dose vials and reduced the prices of two smaller doses of the weight-loss drug for self-pay patients. The ...
Protagonist Therapeutics (PTGX) Gets a Buy from Truist Financial
In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Protagonist Therapeutics (PTGX – Research ...
Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts
EPS and revenue topped estimates, but analysts cite Medicare changes and MS declines as headwinds. Leqembi and Skyclarys remain key growth drivers.
Hosted on MSN29d
Veru's experimental drug helps older obese patients on Wegovy preserve muscle
"We believe weight loss of the combined drugs and safety are (the) key metrics investors are looking for," Truist Securities analyst Srikripa Devarakonda said, adding that Veru's data "attempts to ...
Seeking Alpha1mon
Hims & Hers in focus as Eli Lilly obesity drug sales disappoint
While Ricks said all tirzepatide doses were available throughout the quarter in the U.S., and the company continues to expand its manufacturing footprint, Truist analyst Srikripa Devarakonda ...
Veru's experimental drug helps older obese patients on Wegovy preserve muscle
Veru said on Monday its experimental drug in combination with Novo Nordisk's weight-loss treatment Wegovy, helped preserve muscle in older patients with obesity, meeting the main goal of a mid-stage ...